Pancreatic Cancer Research

ResearcherHoward Hughes Medical InstituteActive in the last 2 years

Anne Marie Lennon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0005-6811-384X; OpenAlex author ID A5022110796; NIH RePORTER profile ID 14547647. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 1)
Trials
0
Grants
1
Labs led
0
Collaborators
135
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: none · 2016: 3 papers · 2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: 4 papers · 2021: 1 paper · 2022: 4 papers, 1 grant · 2023: 2 papers · 2024: 2 papers

Papers 26

  1. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. Co-author DOI 10.1001/jamaoncol.2024.1930↗
  2. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer. Co-author DOI 10.1200/jco.23.01573↗
  3. Screening for pancreatic cancer has the potential to save lives, but is it practical? Co-author DOI 10.1080/17474124.2023.2217354↗
  4. A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising… Co-author DOI 10.1097/sla.0000000000005904↗
  5. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2020.11.006↗
  6. Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2021.10.008↗
  7. Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. Co-author DOI 10.1093/jnci/djac167↗
  8. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  9. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  10. Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04230-z↗
  11. Early detection of pancreatic cancer. Co-author DOI 10.1016/s2468-1253(19)30416-9↗
  12. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  13. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  14. Screening for Pancreatic Cancer—Is There Hope? Co-author DOI 10.1001/jamainternmed.2019.3323↗
  15. Chronic pancreatitis-like changes in individuals at high risk for the development of pancreatic cancer: What is the significance? First author DOI 10.1016/j.gie.2019.01.023↗
  16. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Co-author DOI 10.1093/annonc/mdz200↗
  17. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Co-author DOI 10.1053/j.gastro.2018.05.035↗
  18. Metastatic Pancreatic Adenocarcinoma in a Patient With Chronic Calcific Pancreatitis and a Heterozygous SPINK1 c.194+2T>C Mutation. Co-author DOI 10.1097/mpa.0000000000001015↗
  19. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cance… Co-author DOI 10.1136/gutjnl-2015-311166↗
  20. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2015.10.010↗
  21. Metastatic pancreatic adenocarcinoma associated with chronic calcific pancreatitis and a heterozygous SPINK1 N34S mutation. Co-author DOI 10.1016/j.pan.2016.06.006↗
  22. Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management. Co-author DOI 10.1097/sla.0000000000001156↗
  23. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Co-author DOI 10.1158/0008-5472.can-14-0734↗
  24. Concomitant pancreatic adenocarcinoma in a patient with branch-duct intraductal papillary mucinous neoplasm. Last author DOI 10.3748/wjg.v20.i27.9200↗
  25. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Co-author DOI 10.1016/j.cgh.2012.11.016↗
  26. Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy. Co-author DOI 10.1016/j.gie.2012.07.006↗

Grants 1

  1. Core 2: Biospecimen/Pathology Core P50CA062924↗

Closest collaborators

The 25 strongest of 135 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Goggins · 14 shared papers, 1 shared grant, 2013–2024 · strength 1.70
  2. Ralph H. Hruban · 14 shared papers, 1 shared grant, 2013–2024 · strength 1.52
  3. Marcia Irene Canto · 14 shared papers, 2012–2024 · strength 1.40
  4. Alison P. Klein · 10 shared papers, 1 shared grant, 2014–2024 · strength 1.36
  5. Jin Peng He · 9 shared papers, 2016–2024 · strength 0.98
  6. Elliot K. Fishman · 9 shared papers, 2014–2024 · strength 0.86
  7. Eun Ji Shin · 9 shared papers, 2012–2024 · strength 0.78
  8. Richard Andrew Burkhart · 6 shared papers, 2020–2024 · strength 0.74
  9. Amanda L. Blackford · 5 shared papers, 2018–2024 · strength 0.63
  10. Christopher Lee Wolfgang · 8 shared papers, 2014–2022 · strength 0.52
  11. Nicholas Jason Roberts · 4 shared papers, 2021–2023 · strength 0.49
  12. Takeichi Yoshida · 3 shared papers, 2022–2024 · strength 0.46
  13. Robert A. Anders · 2 shared papers, 1 shared grant, 2021–2022 · strength 0.45
  14. Daniel A. Laheru · 5 shared papers, 2016–2022 · strength 0.42
  15. Matthew John Weiss · 6 shared papers, 2014–2021 · strength 0.39
  16. Ihab R. Kamel · 5 shared papers, 2013–2024 · strength 0.38
  17. Bert Vogelstein · 2 shared papers, 1 shared grant, 2014–2022 · strength 0.38
  18. Kenneth W. Kinzler · 2 shared papers, 1 shared grant, 2014–2022 · strength 0.38
  19. Sapna Syngal · 4 shared papers, 2013–2024 · strength 0.35
  20. Elizabeth M. Jaffee · 1 shared paper, 1 shared grant, 2021–2022 · strength 0.35
  21. Atif Zaheer · 4 shared papers, 2018–2022 · strength 0.35
  22. Vikesh K. Singh · 5 shared papers, 2012–2022 · strength 0.35
  23. James R. Eshleman · 2 shared papers, 2023–2024 · strength 0.35
  24. Ammar A. Javed · 4 shared papers, 2019–2022 · strength 0.33
  25. Randall E. Brand · 3 shared papers, 2020–2024 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.